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Influence of Linker Length and Composition on Enzymatic Activity
and Ribosomal Binding of Neomycin Dimers
Derrick Watkins,a Sunil Kumar,b* Keith D. Green,c Dev P. Arya,a,b Sylvie Garneau-Tsodikovac
Nubad LLC, Greenville, South Carolina, USAa; Department of Chemistry, Clemson University, Clemson, South Carolina, USAb; Department of Pharmaceutical Sciences,
University of Kentucky, BioPharm Complex, Lexington, Kentucky, USAc
The human and bacterial A site rRNA binding as well as the aminoglycoside-modifying enzyme (AME) activity against a series of
neomycin B (NEO) dimers is presented. The data indicate that by simple modifications of linker length and composition, sub-
stantial differences in rRNA selectivity and AME activity can be obtained. We tested five different AMEs with dimeric NEO
dimers that were tethered via triazole, urea, and thiourea linkages. We show that triazole-linked dimers were the worst sub-
strates for most AMEs, with those containing the longer linkers showing the largest decrease in activity. Thiourea-linked dimers
that showed a decrease in activity by AMEs also showed increased bacterial A site binding, with one compound (compound 14)
even showing substantially reduced human A site binding. The urea-linked dimers showed a substantial decrease in activity by
AMEs when a conformationally restrictive phenyl linker was introduced. The information learned herein advances our under-
standing of the importance of the linker length and composition for the generation of dimeric aminoglycoside antibiotics capa-
ble of avoiding the action of AMEs and selective binding to the bacterial rRNA over binding to the human rRNA.
Although aminoglycosides (AGs) have recently been exploredas antiviral, antiprotozoal, and antifungal agents and a poten-
tial treatment for genetic disorders associated with premature ter-
mination codons, they remain best known for their use as broad-
spectrum antibiotics (1, 2). To elicit their antibacterial response,
AGs bind to a highly conserved set of nucleotides on helix 44 (h44)
of the bacterial 16S rRNA (3–5). To a lesser extent, AGs have also
been shown to bind to the mammalian ribosomes, and efforts
have been devoted to achieve higher selectivity of these drugs to-
ward their bacterial target (6–8). Three main groups of AGs have
been structurally defined based on the substitution pattern of their
common 2-deoxystreptamine (2-DOS) ring: (i) the monosubsti-
tuted 2-DOS AGs (e.g., apramycin and hygromycin), (ii) the 4,5-
disubstituted 2-DOS AGs (e.g., butirosin, neomycin B [NEO],
paromomycin, and ribostamycin), and (iii) the 4,6-disubstituted
2-DOS AGs (e.g., amikacin, kanamycin, tobramycin, etc.). Over
the last 70 years of use, the emergence of resistance to AGs has
greatly limited their effectiveness as antibiotics. Among the resis-
tance mechanisms known to affect AGs, namely, decreased up-
take, efflux pumps, ribosomal mutation or modification by meth-
yltransferases, and the acquisition of aminoglycoside-modifying
enzymes (AMEs), the latter is the most prominent. Three families
of AMEs that chemically modify amine and hydroxyl moieties
have evolved to help bacteria evade the action of these drugs: the
AG N-acetyltransferases (AACs), O-phosphotransferases (APHs),
and O-nucleotidyltransferases (ANTs) (9, 10). NEO (compound
1; Fig. 1), a potent antibacterial, is mainly sold for topical use due
to its significant ototoxicity. A number of purified AMEs, such as
AAC(6=)-Ie/APH(2)-Ia (11), AAC(3)-IV (12), ANT(4=)-Ia (13),
and APH(3=)-IIIa (14, 15), among others, have been found to
modify NEO in vitro and to limit its effectiveness in vivo (7, 16).
NEO dimers have been previously reported to bind the bacterial A
site with differing affinities and showed large differences in bacte-
rial inhibition (17).
Here, we report our studies on the activities of a number of
AMEs with NEO dimers (Fig. 1). Additionally, a screening assay
for studying the selectivity of these dimers for binding to the bac-
terial A site versus human A site rRNA is presented. Since any
modification to an existing AG is expected to affect its binding,
transport, and resistance mechanisms, work is needed to map the
effect of modifications on such factors. In this report, we investi-
gate how linker modification in NEO dimers influences binding of
the drug to its ribosomal target, its selectivity in binding to bacte-
rial versus human ribosome, and its influence on resistance en-
zymes that modify NEO.
MATERIALS AND METHODS
Materials and instrumentation. The Eis (18), AAC(6=)-Ie/APH(2)-Ia
(11) (Note: AAC(6=)-Ie/APH(2)-Ia was used only for its acetyltransferase
activity and is referred to as AAC(6=)-Ie from here on), AAC(6=)-Ib= (19),
AAC(3)-IV (12), AAC(2=)-Ic (20), and APH(2)-Ia (19) enzymes were
expressed and purified as previously described. Acetyl-coenzyme A (Ac-
CoA), 5,5=-dithiobis(2-nitrobenzoic acid) (DTNB), GTP, NADH, phos-
phoenolpyruvate (PEP), and a pyruvate kinase lactic dehydrogenase (PK-
LDH) mixture were purchased from Sigma-Aldrich (Milwaukee, WI).
The AG neomycin B (NEO) (compound 1) and 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased
from AK Scientific (Mountain View, CA). The NEO dimers with triazole
linkers (compounds 2 to 8), urea linkers (compounds 9 to 12), and thio-
urea linkers (compounds 13 to 18) were synthesized as previously de-
scribed (Fig. 1; note that the DPA numbers previously reported for these
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NEO dimers appear in parentheses in this figure) (21–23). The methicil-
lin-resistant Staphylococcus aureus (MRSA) strain was a gift from David H.
Sherman (University of Michigan, MI), and all other strains were donated
by Paul J. Hergenrother (University of Illinois at Urbana-Champaign, IL).
The pET28a plasmid containing the APH(3=)-Ia gene (24) was a generous
gift from Gerald D. Wright (McMaster University, Canada). The 96-well
plates were purchased from Thermo Fisher Scientific (Waltham, MA).
UV-visible light (UV-Vis) assays were monitored on a SpectraMax M5
plate reader.
Determination of aminoglycoside-modifying enzyme activity
against novel NEO dimers by UV-Vis assays. To determine if various
AMEs chemically added functionalities to our NEO dimers, we used pre-
viously developed assays to visualize the transformation of these com-
pounds (Fig. 2) (11). All reactions were monitored at 25°C [with the
exception of those with AAC(6=)-Ie and APH(2)-Ia, which were moni-
tored at 37°C] on a SpectraMax M5 microplate reader and performed at
least in duplicate. All rates were normalized to that of NEO (compound 1)
(Fig. 2).
(i) Acetylation. The activities of several AG acetyltransferases
[AAC(6=)-Ie, AAC(6=)-Ib=, AAC(3)-IV, AAC(2=)-Ic, and Eis] were deter-
mined by monitoring the coupling of the released free sulfhydryl group of
CoA with DTNB at 412 nm (ε 14,150 cm1 M1). Briefly, reaction mix-
tures (200 l) containing antibiotic compound (100 M) and AcCoA
(500 M for Eis and 150 M for all other AG acetyltransferases) were
incubated with the AG acetyltransferases [0.125 M for AAC(3)-IV and
AAC(2=)-Ic and 0.5 M for all remaining AG acetyltransferases] in the
presence of DTNB (2 mM) and the appropriate buffer [50 mM morpho-
lineethanesulfonic acid, pH 6.6, for AAC(6=)-Ie and AAC(3)-IV; 50 mM
Tris-HCl, pH 7.5, for AAC(6=)-Ib; 100 mM sodium phosphate, pH 7.4, for
AAC(2=)-Ic; and 50 mM Tris-HCl, pH 8.0, for Eis]. Reactions were mon-
itored by taking measurements every 30 s for 30 min. Initial rates of the
reactions were calculated using the first 5 min of the reaction.
(ii) Phosphorylation. The phosphorylation activities of APH(2)-Ia
and APH(3=)-Ia [purified identically to APH(2)-Ia] (19) were monitored
at 340 nm through the consumption of NADH in the enzyme-coupled
response to the production of ADP. Reaction mixtures (200 l) contain-
ing antibiotic compound (100 M), Tris-HCl [50 mM, pH 8.0, for
APH(2) or HEPES, pH 7.5, for APH(3=)-Ia], MgCl2 (10 mM), KCl (40
mM), NADH (0.5 mg/ml), PEP (2.5 mM), GTP (2 mM), and PK-LDH (4
l) were initiated by the addition of the AG phosphotransferase (1 M).
Reactions were monitored by taking measurements every 30 s for 30 min.
Initial rates were determined using the first 5 min of the reaction.
rRNA A site binding screening. The Escherichia coli A site model (5=-
GGCGUCACACCUUCGGGUAAGUCGCC-3=) and the human A site
model (5=-GGCGUCGCUACUUCGGUAAAAGUCGCC-3=, with bold
characters indicating where the human sequence differs from the E. coli
sequence) (Fig. 3C) were synthesized using standard phosphoramidite
solid-phase synthesis with a 2=-acetoxy ethyl orthoester (2=-ACE) protect-
ing group (Thermo Scientific). All RNA oligonucleotides were depro-
tected before use according to the manufacturer’s protocols, and the de-
protection buffer was removed by evaporation using a SpeedVac
(GeneVac). The RNA oligonucleotides were resuspended in diethyl pyro-
carbonate-treated H2O (OmniPur) to the desired concentration.
Compounds 1 to 18 were screened using an F-NEO (Fig. 3A) competitive
binding assay, as previously described (17, 25). Briefly, the displacement assay
was performed with each compound (0.3 M) and F-NEO–A site complex
FIG 1 Structures of NEO (compound 1) and its dimers (compounds 2 to 18) used in this study.
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(0.1 M) using 100 reads per well at an excitation/emission of 485/535 nm.
All experiments were performed in buffer containing MOPSO (10 mM, pH
7.0), NaCl (50 mM), and EDTA (0.4 mM). The displacements of F-NEO by
compounds 1 to 18 were determined by the increase in fluorescence mea-
sured after the addition of the compound to wells of a 96-well plate containing
F-NEO–A site complex compared to the fluorescence of F-NEO–A site com-
plex alone (F). The percentage of binding was normalized from the ratio of
the change in fluorescence by addition of the test compound (FDrug)
with the change in fluorescence by addition of NEO (compound 1) (FNEO),
using the following equation: % binding  (FDrug/FNEO)  100.
MIC value determination. MIC values were determined using the
microdilution method as outlined in the CLSI Antimicrobial Susceptibil-
ity Testing Standard. Several strains of S. aureus (USA 100, USA 200, USA
300, USA 600, ATCC 29213, and one MRSA strain) and one Bacillus cereus
(ATCC 11778) strain were tested in Mueller-Hinton broth. Cultures were
grown for 16 to 24 h before determination of the MIC values by visual
inspection and confirmation with MTT staining. MIC values for these
eight bacterial strains along with those of an additional S. aureus (ATCC
33591) strain previously reported are presented in Table 1.
Identification of AMEs in eight bacterial strains. To determine the
AME genes present in each of the nine bacterial strains selected (three
ATCC strains, four clinically isolated strains, and two additional MRSA
strains), colonies were picked and subjected to PCR analysis. We used
primer probes previously reported to detect the genes encoding AAC(6=)-
Ib, AAC(3)-IV, ANT(2)-Ia, and APH(3=)-Ia (26). An initial 5 min at 95°C
was used to lyse the bacterial cell and denature the DNA. For 35 cycles, the
samples were subjected to 2 min at 95°C, 1 min at 58°C, and 1 min at 72°C.
After the 35 cycles, the reactions were held at 72°C for 10 min and then
analyzed on a 1.5% agarose gel. Expected band sizes were 482 bp [aac(6=)-
Ib], 230 bp [aac(3)-IV], 534 bp [ant(2)-Ia], and 624 bp [aph(3=)-Ia]
(Fig. 4).
RESULTS
Effect of AMEs on NEO dimers 2 to 18. When tested against var-
ious AACs and APHs, the NEO dimers 2 to 18 displayed various
levels of modification by these resistance enzymes (Fig. 2). In gen-
eral, all AMEs displayed equal or reduced activity toward the tri-
azole-linked NEO dimers (compounds 2 to 8) compared to the
parent AG NEO (compound 1), with the exception of AAC(6=)-
Ib= for which the activity toward compounds 2 to 8 was increased
by up to 235% that of standard 1 (Fig. 2A). Interestingly, contrary
to the trend observed for AAC(6=)-Ib=, the NEO dimers 2 to 8 were
all found to be extremely poor substrates of another AAC(6=)
enzyme, the bifunctional AAC(6=)-Ie/APH(2)-Ia (for which only
the AAC(6=) activity was tested), with a maximum activity ob-
served of 7%. The APH(2)-Ia enzyme alone was also found to be
completely inactive against compounds 2 to 8. Promising results
were also observed against the AAC(3)-IV enzyme, which dis-
played from 0% to 50% activity against compounds 3 to 8 com-
pared to that of compound 1. Compound 8 was found to be the
most recalcitrant to the action of AMEs by being modified only by
AAC(2=)-Ic (51% compared to compound 1) and basically no
other AMEs.
As observed for the triazole-linked NEO dimers 2 to 8, the
initial rate of acetylation of the urea-linked NEO dimers 9 to 12
was greatly increased (159% to 342%) by AAC(6=)-Ib= (Fig. 2B).
Similarly, the activity of AAC(2=)-Ic was increased by 145% to
241% for compounds 9 to 12 compared to that of the parent NEO
(compound 1). Compounds 10 and 11 showed an increase in their
initial rate of phosphorylation by APH(2)-Ia (309% and 458%,
respectively) while compounds 9 and 12 were not phosphorylated
by this enzyme. All the urea-linked NEO dimers displayed slower
initial rates of acetylation with AAC(3)-IV (18% to 46%) and Eis
(21% to 80%). The AAC(6=)-Ie/APH(2)-Ia enzyme was found to
acetylate all urea-based linked dimers (compounds 9 to 12) with
an efficiency similar to that of compound 1 (67% to 116%), with
the exception of compound 11, which was not acetylated by this
bifunctional enzyme.
FIG 2 Bar graphs showing the relative enzymatic modification initial rates of
the listed AACs and APHs with NEO (compound 1) and its dimers 2 to 18. All
rates were normalized to that of NEO (compound 1), which was used for the
synthesis of the dimers. Graphs are presented for (A) the triazole-linked NEO
dimers, (B) the urea-linked NEO dimers, and (C) the thiourea-linked NEO
dimers.
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Dimers with a thiourea linker (compounds 13 to 18) displayed
mixed initial rates of activity compared to that of compound 1
(Fig. 2C). As observed for urea-linked NEO dimers 9 to 12, the
initial rate of acetylation of thiourea-linked NEO dimers 13 to 18
was generally increased by AAC(2=)-Ic and AAC(6=)-Ib=. Com-
pound 13 showed increased initial rates of modification by
AAC(2=)-Ic (200%), AAC(6=)-Ib= (349%), and APH(2)-Ia
(481%), and reduced rates of acetylation by AAC(6=)-Ie/
APH(2)-Ia (21%), AAC(3)-IV (17%), and Eis (35%). Com-
pound 14 gave results similar to those observed for compound 13,
with the exception of APH(2)-Ia (15%) that displayed low phos-
phorylation activity and AAC(2=)-Ic (96%) that displayed activity
similar to that of the enzyme against compound 1. Compounds 15
and 17 behaved similarly to compound 13 but were not phosphor-
ylated by APH(2)-Ia. Compound 16 had an activity profile sim-
ilar to that of compound 13 but with a slightly elevated rate of
acetylation by AAC(6=)-Ie/APH(2)-Ia (119%). Compound 18
displayed an increase in its rate of acetylation by AAC(6=)-Ib=
(328%) but low to no modification by all other AMEs (0% to
58%) was observed.
Interestingly, all compounds displayed reduced phosphoryla-
tion rates by APH(3=)-Ia, which is an APH particularly adept at
deactivating NEO. The fastest reaction rate was observed with
compound 11 (52%), and all other compounds had a relative rate
between 15% and 50% that of unmodified NEO. Despite the fact
that all NEO dimers have two equivalents of the 3=-hydroxyl
group, the reduced rates suggest that the resistance caused by this
enzyme would generally not affect the compounds greatly.
F-NEO competitive binding screen. We have previously re-
ported the binding of dimeric AGs to model bacterial A site rRNA
using the F-NEO displacement assay (17). Here, we have ex-
panded the utility of the assay to include the model human A site
(Fig. 3B). Most NEO dimers in the library bound to E. coli and the
human model of the ribosomal A site with a relative affinity that
was similar to that of NEO (compound 1). Four of the triazole-
linked NEO dimers (compounds 2 and 4 to 6) bound the two A
site models with similar or greater affinity than NEO (compound
1). The remaining three triazole-linked NEO dimers (compounds
3, 7, and 8), which contain longer and/or more flexible linkers,
bound with lower affinity to the human (50% of the binding
affinity of NEO [1]) and E. coli (15% of the binding affinity of
NEO [1]) binding sites. In general, the urea-linked NEO dimers
bound weakly to the E. coli and human model A sites, with com-
pounds 9 to 12 displacing F-NEO from the A site by less than 10%
relative to NEO (compound 1). The only exceptions were the
urea-linked NEO dimers 12, found to have a notable affinity for
the E. coli A site (34% displacement of F-NEO compared to com-
pound 1), and 9, found to have a notable affinity for the human A
site (30% displacement of F-NEO compared to compound 1). As
for the thiourea-linked NEO dimer series, compounds 14, 16, and
18 had a higher relative affinity for the E. coli and human A sites
than did the urea-linked NEO dimers. Within the thiourea-linked
FIG 3 F-NEO competitive binding screen. (A) Structure of the F-NEO probe
used in this study. (B) Bar graph showing the relative rRNA binding of NEO
dimers 2 to 18 normalized to NEO (compound 1). NEO (compound 1) and the
triazole-, urea-, and thiourea-linked NEO dimers are represented in purple,
green, yellow, and orange, respectively. The competitive binding screen of E.
coli and human model ribosomal A site are represented in pale color bars on
the left and dark color bars on the right for each NEO dimer, respectively.
(C) The E. coli A site rRNA (top) and mammalian A site rRNA (bottom) used
for the screening assay using F-NEO. The differences between the E. coli and
human sequence are highlighted by the filled circles in the secondary structure
(left) of the human A site. Key residues of the binding pocket for AGs are
labeled in the three-dimensional representation (right) of the E. coli and hu-
man A sites. The three dimensional structures were modeled from PDB ID:
1PBR for the E. coli A site and PDB ID: 2FQN for the human A site using only
the residues present in the two structures. The bases of the representations are
color coded red (guanine), pale orange (cytosine), blue (uracil), and green
(adenine) and numbered according to the E. coli ribosome.
Watkins et al.
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NEO dimers, some interesting trends emerged. The compound
with the shortest linkage, compound 13, showed weak binding
relative to compound 1 and little differential binding to the two
rRNAs. Going from dimer 15 to a longer linker in dimer 16 in-
creased the overall affinities but eliminated the selectivity of 15
toward the human A site. Similarly, going from dimer 17 to a
longer linker in dimer 18 increased the overall affinities but re-
moved the bacterial rRNA selectivity of dimer 17. Overall, a few of
the lower affinity dimers (compounds 12 and 17) showed a better
selectivity for the bacterial rRNA model A site relative to that of
the human version. In contrast, dimers 3, 9, and 15 showed a
modest selectivity for the human A site rRNA. While the exact
affinities of these compounds remain to be determined, the assay
used (25), as shown before, is a reliable predictor of the effects of
minor modifications to AG structure on rRNA binding. Our data
suggest that such minor modifications in AG dimer linkages alone
may lead to differential selectivity toward human versus bacterial
model rRNAs and should be further explored.
MIC determination. All compounds were tested against eight
bacterial strains (Table 1). All MRSA strains were resistant to NEO
and most of the derivatives with the exception of the untyped
MRSA and S. aureus USA 100, which displayed MIC values of 12.5
M and 3.13 M, respectively, in the presence of compound 18. S.
aureus USA 200, USA 300, and USA 600 also showed less resis-
tance than NEO with the same compound. S. aureus ATCC 29213
showed the best susceptibility to the NEO dimers with all com-
pounds showing a similar MIC value to that of NEO with the
exception of compounds 13, 11, 10, and 16. B. cereus MIC values
ranged from 6.25 M to 25 M, 4-fold to 16-fold higher values
than that of NEO (1.56 M).
The genetic probing provided insight into potential resistance
mechanisms of the bacterial strains tested. Of the strains probed,
S. aureus USA 100 had three AME genes, aac(6=)-Ib, aac(3)-IV,
and aph(3=)-Ia; S. aureus USA 200 and USA 300 each had two
AME genes, aac(6=)-Ib and aph(3=)-Ia; and the MRSA strain had
aac(6=)-Ib in its genome. B. cereus also had three AME genes con-
tained within its DNA, aac(6=)-Ib, aac(3)-IV, and aph(3=)-Ia
.While there are AMEs contained within the strains tested herein
and previously, this panel is far from complete and does not take
into account other modes of resistance. S. aureus ATCC 29213
contains none of the four AMEs probed for, which agrees with the
low MIC values for that strain. S. aureus USA 600 and S. aureus
ATCC 33591 also show no AMEs in their respective genomes;
however, these are methicillin-resistant phenotypes which are
known to have many different mechanisms of resistance that can
affect the efficacy of AGs.
DISCUSSION
Within the triazole-linked dimer series, compound 2, containing
three methylene groups between the triazoles, showed the highest
rate of modification. Conversely, compound 8, with the dode-
canediol linker between the triazole groups, shows the least
amount of modifications, suggesting that this linker would be the
best to overcome modification by AMEs. The decrease in activity
observed with compound 8 may arise if the long linker either (i)
prevents the individual NEO molecules in the dimer from binding
to the active site or (ii) prevents binding of AcCoA to the enzyme-
substrate complex. With the exception of compound 4, the only
linker that includes branching, and compound 5, containing a
phenyl linker, as the linker length increases, fewer AMEs modify
the NEO molecules in their respective dimers.
The dimers with the urea linkages (compounds 9 to 12) gener-
ally displayed greater activity than those in the triazole series
(compounds 2 to 8). The most direct comparison can be drawn
from compounds 3 and 9, which contain a 6-carbon linker be-
tween their defining functional groups. The difference in the en-
zymatic-modification profile of these compounds can be attrib-
uted to the method of linking the two NEO molecules and suggests
that the triazole linkage is less susceptible to enzymatic modifica-
tion than the urea linkage. From the data in the urea-linked NEO




















1 (NEO) 	50 	50 	50 	50 3.13 159.5 	50 1.56
2 	50 	50 	50 	50 1.56 	44.4 	50 12.5
3 	50 	50 	50 	50 3.13 43.2 	50 12.5
4 	50 	50 	50 	50 6.25 	42.6 	50 25
5 	50 	50 	50 	50 3.13 20.1 	50 25
6 	50 	50 	50 	50 1.56 	44.2 	50 25
7 	50 	50 	50 	50 3.13 	41.2 	50 	25
8 25 25 25 25 3.13 20.1 25 25
9 	50 50 	50 	50 3.13 	43.6 	50 12.5
10 	50 	50 	50 	50 	50 	41.7 	50 	25
11 	50 	50 	50 	50 	50 	43.8 	50 	25
12 	50 	50 	50 	50 12.5 	43.8 	50 	25
13 	50 	50 	50 	50 25 	46.9 	50 	25
14 	50 	50 	50 	50 3.13 43.9 	50 12.5
15 	50 50 	50 	50 3.13 	42.2 50 6.25
16 	50 	50 	50 	50 	50 20 	50 	25
17 	50 25 	50 	50 3.13 	27.3 	50 25
18 25 25 25 50 3.13 	39.7 12.5 	25
a The data for these S. aureus isolates were previously reported in reference 17. They have been included as the resistance enzymes for this strain and were probed by PCR (see Fig. 4).
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dimers, a long linker, such as that in compound 10, reduces the
number of modifications by enzymes as well as the rate of modi-
fication that can occur on NEO (compound 1). Likewise, confor-
mationally restricting the rotation of the dimer may also reduce
the ability of enzymes to modify NEO (compound 1), as seen in
compounds 11 and 12. The para-substitution of compound 12
shows reduced activity compared to that of compound 11 for all
enzymes except AAC(6=)-Ie. From the urea-linked NEO dimers,
compound 10, containing 10 methylene groups separating the
urea linkages, showed the highest rates of modification while com-
pound 12, linked via a para-phenyl linker, showed the least mod-
ification. Within the urea-linked NEO dimers, the best linker to
minimize AME activity would be a conformationally restricted
para-substituted phenyl group.
Compounds in the thiourea-linked dimers (compounds 13 to
18) showed similar enzymatic-modification profiles to those of
the urea-linked dimers, suggesting that the oxygen-to-sulfur re-
placement does not greatly affect AME modification profiles. In
this group, compound 13, containing two NEO molecules directly
linked via a thiourea, showed the highest rates of modification.
Compound 14, with three methylene units between two thiourea
moieties, showed the lowest average rates of modifications, fol-
lowed closely by compound 18. These data suggest that within the
thiourea-linked NEO dimers, a relatively short 3-carbon chain
would be an optimum choice. Additionally, the long polyethyl-
eneglycol linker in compound 18 showed substantial activity only
with AAC(6=)-Ib=, suggesting that it would be a good linker to
avoid modification by AMEs. Directly comparing compounds 2
and 14 with the major difference being a triazole versus a thiourea,
there is little difference in the rates of modification with the ex-
ception of AAC(3)-IV, where compound 2 displayed a 10-fold
higher rate of conversion than that of compound 14. This result
suggests that when choosing a short methylene linker length, a
thiourea conjugation would be superior to a triazole.
While MIC values were previously determined with these com-
pounds (17), eight additional strains were tested herein. Noting
the excellent MIC values previously reported with S. aureus ATCC
25923 and the moderate activity with S. aureus ATCC 33591, a
methicillin-resistant strain, we tested several more strains of S.
aureus and the Gram-positive B. cereus (Table 1). While most of
the compounds were as effective at killing S. aureus ATCC 29213
as they were at killing S. aureus ATCC 25923, only compound 18
stood out against the MRSA strains, showing significantly reduced
MIC values. This structure should be the next stepping point for
this series of NEO dimers, as it is effective against strains contain-
ing AG resistance enzymes and those that did not show the se-
lected genes.
Other NEO dimers have been generated by using a disulfide
approach, where each NEO molecule is attached to an aliphatic
thiol and the thiols are oxidized, forming a disulfide bond in the
linker (27), and using naphthalene diimide as the central linker
(28, 29). Each type of dimer has improved binding to the tested
ribosome compared to NEO; however, the effect of these dimers
on bacteria has not been tested. These compounds reinforce the
presented data showing that dimerization of NEO enhances bind-
ing to the ribosome, given the correct linker.
Overall, the longer linkers, containing a triazole linkage as the
method of combining two NEO molecules, lead to a NEO dimer
that most effectively avoids modification by AMEs. On the other
hand, some of these long linkers (e.g., in compounds 7 and 8) lead
to reduced binding to the model A site rRNA compared to that of
NEO. Similar observations can be made from the urea-linked
dimers, where reduction in AME activity also and a loss of bacte-
rial rRNA binding (compounds 10 and 12) is observed. Com-
pound 10, however, showed much reduced binding to the human
A site rRNA, suggesting a binder more selective for bacteria. Fi-
nally, the best thiourea-linked dimers that avoid AME modifica-
tion (compounds 14 and 18) also showed a high degree of binding
to the bacterial rRNA, with dimer 14 also showing increased se-
lectivity in binding, as evidenced by reduced binding to human A
site. It should be noted here that all but two of the NEO dimers
reduced the initial rate of acetylation for Eis. This is significant due
to the multiacetylating ability this AME has. We have documented
this enzyme to modify the 3-amino, 2=-amino, 6=-amino, and
1-amino groups of certain AGs (18, 30); while the modified posi-
tions of NEO are as of yet unresolved, the fact that these com-
pounds hinder Eis ability to transfer an acetyl group is significant.
Further work to optimize the selectivity in ribosomal binding and
AME activity within a modified AG will be necessary for the de-
velopment of more potent antibacterials. This work is under way
in our laboratories.
FIG 4 Agarose gels of PCRs probing for AME genes in various ATCC strains
and clinical isolates. Strains of (A) clinically isolated MRSA USA 100, USA 200,
USA 300, and USA 600, (B) S. aureus ATCC 29213, S. aureus ATCC 33591, and
an uncategorized MRSA, and (C) B. cereus ATCC 11778 tested for aac(6=)-Ib
(lane 1), aac(3)-IV (lane 2), ant(2)-Ia (lane 3), and aph(3=)-Ia (lane 4). L1 and
L2 represent 100-bp and 1-kb DNA ladders, respectively. Expected band sizes
are as follows: aac(6=)-Ib, 482 bp; aac(3)-IV, 230 bp; ant(2)-Ia, 534 bp;
aph(3=)-Ia, 624 bp.
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